Protein Engineering, Antibody Conjugation, Services

BrickBio is at the forefront of biotechnology, specializing in the development of advanced protein therapeutics through its innovative platform that utilizes unnatural amino acids (UAAs). The company's core technology, the Evolved tRNA Localization (ETRNAL) Platform, allows for the precise incorporation of synthetic amino acids at any site within a protein backbone. This capability addresses the limitations of traditional conjugation methods, which often result in unstable and heterogeneous products. By enabling site-specific conjugation, BrickBio's technology enhances the therapeutic index of antibody-drug conjugates (ADCs), making them significantly safer and more effective than existing alternatives. The platform also supports the creation of multi-payload conjugates, which combine distinct therapeutic agents to improve patient outcomes.

In addition to its ADC technology, BrickBio has developed the VADER system, which accelerates the generation of stable mammalian cell lines for UAA incorporation, achieving production rates that are five times faster than competitors. This system allows for the introduction of multiple distinct bioconjugation handles within a single protein, facilitating the development of complex therapeutics. Furthermore, BrickBio's Protein Origami and Synthetic Virology platforms leverage the same core technologies to create novel therapeutic modalities and enhance gene therapy delivery systems. Overall, BrickBio's advancements in protein engineering and bioconjugation are poised to revolutionize the landscape of modern therapeutics, offering new solutions for previously unmet medical needs.

United States

BrickBio's engineered RNA and protein-chemistry platform technology enables custom tailoring of any protein with homogenous, site-specific and site-selective bioconjugation modifications, enabling novel classes of biologics with superior therapeutic windows and characteristics such as half-life, dosage, and efficacy.

 

Having validated its precise and unrestricted conjugation capabilities through pharmaceutical co-development partnerships, the company is building its internal oncology and immunology pipeline by creating unique antibody and bispecific-conjugates while additionally pioneering spatial protein assembly for Precise Protein Origami™.

BrickBio

Company Details